Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer

GARDEN CITY, N.Y., March 23, 2023 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ:XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Dr. Jeff Myers, M.D., Ph.D. as Chief Medical Officer of the Company, effective as of March 27, 2023. Dr. Andrew Colin, the Company’s incumbent Chief Medical Officer, has transitioned to the role of Senior Medical Director Global Clinical Leadership and will remain an integral part of the Beyond Air team. Dr Colin will be working closely with Dr. Myers to ensure a seamless transition. Dr. Myers joins Beyond Air with nearly 15 years of leadership experience as a biopharmaceutical executive overseeing clinical development, clinical operations, and regulatory affairs. Prior to industry, Dr. Myers was a cardiothoracic surgeon for nine years, most recently at Massachusetts General Hospital.

Read more at globenewswire.com